Cargando…

Antisense Therapy Attenuates Phospholamban p.(Arg14del) Cardiomyopathy in Mice and Reverses Protein Aggregation

Inherited cardiomyopathy caused by the p.(Arg14del) pathogenic variant of the phospholamban (PLN) gene is characterized by intracardiomyocyte PLN aggregation and can lead to severe dilated cardiomyopathy. We recently reported that pre-emptive depletion of PLN attenuated heart failure (HF) in several...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eijgenraam, Tim R., Stege, Nienke M., Oliveira Nunes Teixeira, Vivian, de Brouwer, Remco, Schouten, Elisabeth M., Grote Beverborg, Niels, Sun, Liu, Später, Daniela, Knöll, Ralph, Hansson, Kenny M., Amilon, Carl, Janzén, David, Yeh, Steve T., Mullick, Adam E., van der Meer, Peter, de Boer, Rudolf A., Silljé, Herman H. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909937/ https://www.ncbi.nlm.nih.gov/pubmed/35269571 http://dx.doi.org/10.3390/ijms23052427

Ejemplares similares

Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
por: Grote Beverborg, Niels, et al.
Publicado: (2021)

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy
por: Eijgenraam, Tim R., et al.
Publicado: (2021)

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

Review: Precision Medicine Approaches for Genetic Cardiomyopathy: Targeting Phospholamban R14del
por: Deiman, Frederik E., et al.
Publicado: (2022)

A randomized controlled trial of eplerenone in asymptomatic phospholamban p.Arg14del carriers
por: de Brouwer, Remco, et al.
Publicado: (2023)

Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction
por: Verstraelen, Tom E, et al.
Publicado: (2021)

Phospholamban p.Arg14del Cardiomyopathy: A Japanese Case Series
por: Tabata, Tomoka, et al.
Publicado: (2021)

The phospholamban p.Arg14del founder mutation in Dutch patients with arrhythmogenic cardiomyopathy
por: van der Heijden, J. F., et al.
Publicado: (2013)

Recurrent and founder mutations in the Netherlands—Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy
por: van der Zwaag, P. A., et al.
Publicado: (2013)

The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
por: Van Der Heide, M Y C, et al.
Publicado: (2023)

Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
por: te Rijdt, W. P., et al.
Publicado: (2021)

Blocking phospholamban with VHH intrabodies enhances contractility and relaxation in heart failure
por: De Genst, Erwin, et al.
Publicado: (2022)

Optimal echocardiographic assessment of myocardial dysfunction for arrhythmic risk stratification in phospholamban mutation carriers( )
por: Taha, Karim, et al.
Publicado: (2021)

Characterization of Skeletal Muscle Biopsy and Derived Myoblasts in a Patient Carrying Arg14del Mutation in Phospholamban Gene
por: Zanotti, Simona, et al.
Publicado: (2023)

High Resolution Systematic Digital Histological Quantification of Cardiac Fibrosis and Adipose Tissue in Phospholamban p.Arg14del Mutation Associated Cardiomyopathy
por: Gho, Johannes M. I. H., et al.
Publicado: (2014)

Negative Adrenergic Feedback Specific to Phospholamban
por: Hasenfuss, Gerd, et al.
Publicado: (2017)

The Time Has Come to Explore Plasma Biomarkers in Genetic Cardiomyopathies
por: Stege, Nienke M., et al.
Publicado: (2021)

Prevalence and cardiac phenotype of patients with a phospholamban mutation
por: Hof, I. E., et al.
Publicado: (2018)

A hallmark of phospholamban functional divergence is located in the N-terminal phosphorylation domain
por: Fernández-de Gortari, Eli, et al.
Publicado: (2020)

Phospholamban cardiomyopathy: a Canadian perspective on a unique population
por: Cheung, C. C., et al.
Publicado: (2019)

Obesity does not Lead to Imbalance Between Myocardial Phospholamban Phosphorylation and Dephosphorylation
por: Freire, Paula Paccielli, et al.
Publicado: (2014)

Immunoelectron microscopical localization of phospholamban in adult canine ventricular muscle
Publicado: (1987)

Localization of phospholamban in smooth muscle using immunogold electron microscopy
Publicado: (1988)

The role of CaMKII regulation of phospholamban activity in heart disease
por: Mattiazzi, Alicia, et al.
Publicado: (2014)

Tracking nitroxyl-derived posttranslational modifications of phospholamban in cardiac myocytes
por: Mundiña-Weilenmann, Cecilia Beatriz, et al.
Publicado: (2019)

Phospholamban R14del disease: The past, the present and the future
por: Vafiadaki, Elizabeth, et al.
Publicado: (2023)

Phospholamban pentamerization increases sensitivity and dynamic range of cardiac relaxation
por: Funk, Florian, et al.
Publicado: (2023)

Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium
por: Abella, Lina Maria Rayo, et al.
Publicado: (2022)

Phospholamban overexpression in mice causes a centronuclear myopathy-like phenotype
por: Fajardo, Val A., et al.
Publicado: (2015)

Atomistic Structure and Dynamics of the Ca(2+)-ATPase Bound to Phosphorylated Phospholamban
por: Aguayo-Ortiz, Rodrigo, et al.
Publicado: (2020)

Molecular noise filtering in the β-adrenergic signaling network by phospholamban pentamers
por: Koch, Daniel, et al.
Publicado: (2021)

Myofilament Alterations Associated with Human R14del-Phospholamban Cardiomyopathy
por: Kumar, Mohit, et al.
Publicado: (2023)

Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy
por: Kamel, S. M., et al.
Publicado: (2021)

Secondary Structure, Backbone Dynamics, and Structural Topology of Phospholamban and Its Phosphorylated and Arg9Cys-Mutated Forms in Phospholipid Bilayers Utilizing (13)C and (15)N Solid-State NMR Spectroscopy
por: Yu, Xueting, et al.
Publicado: (2014)

Structural basis for allosteric control of the SERCA-Phospholamban membrane complex by Ca(2+) and phosphorylation
por: Weber, Daniel K, et al.
Publicado: (2021)

Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology
por: Alnuwaysir, Ridha I. S., et al.
Publicado: (2021)

Exploring the Correlation Between Fibrosis Biomarkers and Clinical Disease Severity in PLN p.Arg14del Patients
por: van der Voorn, Stephanie M., et al.
Publicado: (2022)

Co-Expression of SERCA Isoforms, Phospholamban and Sarcolipin in Human Skeletal Muscle Fibers
por: Fajardo, Val A., et al.
Publicado: (2013)

Nitroxyl (HNO) targets phospholamban cysteines 41 and 46 to enhance cardiac function
por: Keceli, Gizem, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ojt89s1o1rno53dmsda105rh0f